Search

Displaying results 6571 - 6580 of 10000 in total
  1. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.

  2. Drug

    Interleukin-7

    go.drugbank.com/drugs/DB11997
    Investigational

    Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.

  3. Drug

    Muparfostat

    go.drugbank.com/drugs/DB05808
    Investigational

    Muparfostat (PI-88) is a mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic

  4. Drug

    Flupirtine

    go.drugbank.com/drugs/DB06623
    Investigational

    It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.

  5. Drug

    Benzoylecgonine

    go.drugbank.com/drugs/DB01515
    ExperimentalIllicit

    It is the main pharmaceutical ingredient in the investigational drug Esterom, a topical solution used for the relief of muscle pain that is not FDA approved or on the market in the United States. … It is excreted in the urine of cocaine users after processing in the liver.

  6. Drug

    Edonerpic

    go.drugbank.com/drugs/DB05938
    Investigational

    Edonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.

  7. Drug

    Tosatoxumab

    go.drugbank.com/drugs/DB16557
    Investigational

    by protecting against destruction of host cells mediated by the toxin. … Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin[A191829, L31568, L31573] and thereby preserving human immune cells

  8. Drug

    Tesevatinib

    go.drugbank.com/drugs/DB11973
    Investigational

    Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. … In cell culture models, tesevatinib retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.

    Categories: Receptor, EphB4, antagonists & inhibitors, Receptor, ErbB-2, antagonists & inhibitors
  9. Drug

    NV-18

    go.drugbank.com/drugs/DB05886
    Experimental

    of the gall bladder). … NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer.

  10. Drug

    AG-702

    go.drugbank.com/drugs/DB05836
    Experimental

    This drug is developed by antigenics for the treatment of genital herpes infection and is under phase I of clinical trial. … HSPs are present in all cells in all life forms from bacteria to mammals, and their structure and function are similar across these diverse life forms.